OCM2

Across TCGA pan-cancer cohorts, OCM2 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated OCM2 data layer compared with 4 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher OCM2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated OCM2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and MESO show a favorable association.

LUAD, MESO, and LUSC are the cancer types where OCM2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.769	0.316	.013	60	view →
MESO	DFS	Tertile	All	0.536	0.217	.016	39	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
BRCA	DFS	Tertile	IV	0.175	0.730	.005	36	view →
THCA	DFS	Tertile	IV	0.146	0.795	.004	30	view →
DLBC	OS	Tertile	III,IV	0.154	0.735	.010	28	view →
THYM	OS	Tertile	III,IV	0.212	1.000	.014	18	view →
PRAD	DFS	Tertile	All	0.877	0.940	.024	12	view →
SKCM	OS	Tertile	IV	0.179	0.727	<.001	9	view →
ESCA	OS	Tertile	III,IV	0.552	0.326	.045	6	view →
ACC	OS	Tertile	All	0.288	0.663	.043	3	view →
STAD	DFS	Tertile	IV	0.144	0.459	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

OCM2–LUAD (DFS)

Open the LUAD breakdown →